Literature DB >> 17917538

Platelet contributions to the pathogenesis of systemic sclerosis.

Arnold E Postlethwaite1, Thomas M Chiang.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to focus attention on platelet contributions, in general, to systemic sclerosis. There have also been recent advances in characterization of the phenotype of platelets in systemic sclerosis which will be reviewed. RECENT
FINDINGS: An extensive literature provides strong support for varying degrees of platelet activation and aggregation in different forms and stages of systemic sclerosis. A recent finding is that systemic sclerosis platelets overexpress a specific nonintegrin 65 kDa receptor for type I collagen as well as expressing enhanced phosphilidylinositol-3 kinase as an activation signature. Overexpression of a type I collagen receptor would make systemic sclerosis platelets more susceptible to binding to exposed type I collagen in the subendothelial lining of damaged blood vessels, facilitating the cycle of platelet aggregation and release of preformed bioactive molecules that include a host of inflammatory and fibrogenic, chemokines, cytokines and growth factors. This activation phenotype of systemic sclerosis platelets may be secondary to autoimmunity and driven by cytokines from autoreactive T cells.
SUMMARY: The contributions of platelets to the pathogenesis of systemic sclerosis is likely substantial and may not be adequately represented in gene profiling of systemic sclerosis tissue due to the small amounts of RNA contained in platelets.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917538     DOI: 10.1097/BOR.0b013e3282eeb3a4

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  27 in total

1.  SSc in 2011: From mechanisms to medicines.

Authors:  Luc Mouthon
Journal:  Nat Rev Rheumatol       Date:  2012-01-10       Impact factor: 20.543

Review 2.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

3.  Mean platelet volume seems to be a valuable marker in patients with systemic sclerosis.

Authors:  Serdar Soydinc; Ibrahim Halil Turkbeyler; Yavuz Pehlivan; Gulcimen Soylu; Mehmet Fatih Goktepe; Muhammed Bilici; Orhan Zengin; Bunyamin Kisacik; Ahmet Mesut Onat
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

Review 4.  New lines in therapy of Raynaud's phenomenon.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

Review 5.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 6.  Pharmacotherapy of systemic sclerosis.

Authors:  Arnold E Postlethwaite; L Jeff Harris; Syed H Raza; Swapna Kodura; Titilola Akhigbe
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

7.  Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.

Authors:  Kathryn J Martires; Kristin Baird; Seth M Steinberg; Lana Grkovic; Galen O Joe; Kirsten M Williams; Sandra A Mitchell; Manuel Datiles; Fran T Hakim; Steven Z Pavletic; Edward W Cowen
Journal:  Blood       Date:  2011-07-26       Impact factor: 22.113

8.  Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts.

Authors:  Zhaohong Yin; Laura D Carbone; Mari Gotoh; Arnold Postlethwaite; Alyssa L Bolen; Gabor J Tigyi; Kimiko Murakami-Murofushi; Mitchell A Watsky
Journal:  Rheumatology (Oxford)       Date:  2010-09-07       Impact factor: 7.580

Review 9.  Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!

Authors:  Jelena Čolić; Marco Matucci Cerinic; Serena Guiducci; Nemanja Damjanov
Journal:  J Scleroderma Relat Disord       Date:  2019-06-28

Review 10.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.